TÜBİTAK High Technology Platform Convened at Our University

The interim evaluation meeting of the Target Specific Pan-Cancer Therapies (PAN-TER) platform, which is supported within the scope of the Scientific and Technological Research Council of Turkey (TÜBİTAK) Center of Excellence Support Program (TÜBITAK-1004), was hosted by Karadeniz Technical University (KTU). The meeting was chaired by Prof. Dr. Hamdullah Çuvalcı, Rector of our University. It was attended by representatives of high technology platform members Izmir Biomedicine and Genome Center (IBG), Gebze Technical University, KTU Drug and Pharmaceutical Technology Application and Research Center (KTU-ILAFAR), Abdi İbrahim Pharmaceuticals, Gensenta Pharmaceuticals, and Novagenix Bioanalytical Drug R&D Center.

We are open to cooperation

In his speech at the meeting, our Rector Prof. Dr. Hamdullah Çuvalcı drew attention to the development and transformation of the pharmaceutical industry and said, "I would like to express that in order for our pharmaceutical industry to take part in global competition, we must be a country that can independently realize modern and original applications of pharmaceutical biotechnology. For this, it is necessary to work and produce with a common mind. As Karadeniz Technical University, we will support every work to be done in the field of health and we are open to cooperation."

To be put into practice

The project, carried out by the TÜBİTAK-1004 PAN-TER Platform, aims to establish a network of excellence specializing in biotechnological drug development technologies of molecular and cellular origin and to develop 4 new drugs and 1 companion diagnostic kit through this network. During the meeting, it was pointed out that pharmaceutical biotechnology is important not only in terms of its economic potential but also in terms of its contribution to human welfare by enabling new treatment applications against diseases. It was also announced that the "pan-cancer treatment" concept would be put into practice within the scope of the PAN-TER program, as each drug developed can be used in the treatment of different cancers.

19 October 2023